NasdaqGS:VRTXBiotechs
Vertex (VRTX) Stock Highlights Margin Strength As Launch Costs Climb
Vertex Pharmaceuticals stock entered this earnings release on weaker footing, down over the past month even after a solid run over the last quarter. After the results, the stock moved about 1.7% higher, a modest reaction to what appears to be a more substantial story in the numbers.
The main takeaway is margin resilience in a high-pressure launch year. Vertex reported about US$3.3 billion in Q2 revenue with non-generally accepted accounting principles earnings per share of US$4.73 while...